Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 6215

A Chinese Kuaizhou 1A (KZ-1A) rocket lifted off from the Jiuquan Satellite Launch Center in Inner Mongolia at 06:19 UTC on September 27 lofting a new high-resolution remote sensing satellite into orbit.

The rocket lifted off from Site 95 at Jiuquan, marking the 14th flight of a KZ-1 series rocket. This was also the first KZ-1 launch since the Jilin-1 Gaofen-02C launch in September 2,020 which ended in failure and the loss of its payload.

China’s KZ-1A rocket is manufactured by the ExPace Technology Corporation, an aerospace company owned by the Chinese government, based out of Wuhan in China’s Hubei province. The rocket is capable of delivering payloads of up to 200 kg into a Sun-Synchronous Orbit, and therefore is mainly marketed as a small satellite launch vehicle.

Read more | >

Cloudflare, The internet infrastructure company, already has its fingers in a lot of customer security pots, from DDoS protection to browser isolation to a mobile VPN. Now the company is taking on a classic web foe: email.

On Monday, Cloudflare is announcing a pair of email safety and security offerings that it views as a first step toward catching more targeted phishing attacks, reducing the effectiveness of address spoofing, and mitigating the fallout if a user does click a malicious link. The features, which the company will offer for free, are mainly geared toward small business and corporate customers. And they’re made for use on top of any email hosting a customer already has, whether it’s provided by Google’s Gmail, Microsoft 365 Yahoo, or even relics like AOL.

Cloudflare CEO Matthew Prince says that from its founding in 2,009 the company very intentionally avoided going anywhere near the thorny problem of email. But he adds that email security issues are unrelenting, so it has become necessary. “I think what I had assumed is that hosting providers like Google and Microsoft and Yahoo were going to solve this issue, so we weren’t sure there was anything for us to do in the space,” Prince says. “But what’s become clear over the course of the last two years is that email security is still not a solved issue.”

Read more | >

Epic has developed technology that serves as a digital vaccination verification by binding a person’s identity with their vaccination or lab results and displaying it via QR codes on a smartphone, Wisconsin State Journal reported Sept. 27.

Epic has rolled out technology that serves as a digital vaccination verification by binding a person’s identity with their vaccination or lab results and displaying it via QR codes on a smartphone, Wisconsin State Journal reported Sept. 27.

Seven things to know:

1. The new tech is currently live for 25 million patients, and 70 million to 80 million people will have access to it by the end of 2,022 Nick Frenzer, an Epic implementation executive, told the publication.

Continue reading “Epic deploys tech to verify COVID-19 vaccination status, test results” | >

This year’s deadline for applications is November 15 2021. To learn more, visit https://aws.amazon.com/health/health-equity.

AWS is announcing a new global program to support organizations working to enhance health outcomes for underserved or underrepresented communities. We are providing AWS credits and technical expertise, committing $40 million over three years to help organizations develop solutions to improve health outcomes.

Read more | >

In case this hasn’t been posted here yet.

Ageing is inevitable, but what if everything we’ve come to believe about ageing is wrong and we’re able to choose our lifespans? What if ageing is a disease?

In this week’s #HealthyLongevity #webinar, Prof David Sinclair from Harvard Medical School shares a bold new theory for why we age. Prof Sinclair is also the author of “Lifespan, Why We Age – and Why We Don’t Have To” (https://lifespanbook.com/).

Continue reading “Do we finally have control over ageing? | Prof David Sinclair” | >

To treat lymphoma in dogs, veterinarians have traditionally relied on chemotherapy drugs first designed for people.

Now, the FDA has approved a medication specifically designed to treat canine cancer — and the new approach to chemo drug development might end up helping humans.

Lymphoma in dogs: Lymphoma is a cancer that starts in the cells and tissues of the lymphatic system. It’s one of the most common cancers in dogs, accounting for up to 24% of all new cases and affecting up to 70,000 pets in the U.S. annually.

Continue reading “FDA approves first drug to treat lymphoma in dogs” | >